Early Feasibility Study of a Novel Negative Pressure Wound Therapy Glove for Hand Injuries

NCT ID: NCT05844943

Last Updated: 2024-10-26

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-08-15
• Study Completion Date: 2025-12-01

Brief Summary

Single-center nonrandomized single-arm early feasibility study of participants with soft tissue trauma in the hand. Prior to enrolling participants with hand injuries, the safety of continuous glove use for up to 96 hours without a glove replacement will be assessed on healthy volunteers.

Injured participants will be on study for up to 7 weeks depending on when the final glove is removed.

Screening: Prior to surgery and through 72 hours post-surgery to identify eligible patients

Treatment with Glove: Treatment begins with initial application of the ReHeal Glove and can last up to 7 days (with dressing changes every 48-72 hours unless more frequent changes are requested by the treating physician.)

Follow-up: Up to 6 weeks after final removal of glove to ensure complete wound healing.

Detailed Description

A maximum of 10 participants may be enrolled. Each participants will be enrolled sequentially, with in-depth review of study data from each individual participant before proceeding to the next participant. There will be one and only one participant at a time experiencing glove use. This allows the study team to identify and correct any safety issues before another participant is enrolled and begins glove use. This strategy is in place to minimize risk to participants. Screening data will be reviewed to determine participant eligibility. Participants who meet all inclusion criteria and none of the exclusion criteria will be entered into the study.

Each participant will have the glove applied after surgery. The timing of the initial application could be immediately following surgery or up to 3 days after the surgery, at the discretion of the treating surgeon. Application delays of 1-3 days may be indicated if, in the opinion of the surgeon, the wound would benefit from a period of immobilization prior to donning the glove and allowing for the additional mobility possible with the glove dressing.

Reasons for a potential delay could include minimizing bleeding or oozing after debridement, or for protection of a skin graft. Following current standards of negative pressure wound therapy (NPWT), the wound will be assessed and the glove replaced every 48 to 72 hours. The glove may be assessed by the clinical care team and, if needed, removed and replaced earlier. At each participant encounter, data will be collected by the study team and pressure settings will be documented. At each study visit involving a dressing change, the glove will be removed for closer assessment of the wound and replaced with a new glove. Participants will remain in the study until wound healing or clinical resolution, or study exit. After study exit for each participant, data will be reviewed, and any design changes indicated by the results of the study will be implemented prior to enrollment of the next subject.

The ReHeal Glove and Cardinal Health Negative Pressure Wound Therapy Pro/Pro To Go pump will be used.

Conditions

Hand Injuries

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Soft tissue hand injury

Group Type: EXPERIMENTAL

ReHeal glove with Negative Pressure Wound Therapy (NPWT)

Intervention Type: DEVICE

ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).

Interventions

ReHeal glove with Negative Pressure Wound Therapy (NPWT)

ReHeal glove hand dressing with Negative Pressure Wound Therapy (NPWT).

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• • Persons 22 years or older

• Wound size greater than 1cm2
• Patient will have surgery to treat the wound, warranting the use of a dressing after surgery
• Patient must be able to give informed consent
• Persons who can read and write in English
• Acute, unilateral, and isolated open finger or hand injuries caused by:

• Burn
• Blast
• Abrasion
• Avulsion
• Amputation
• Mangling hand injury
• post-compartment syndrome release ((fasciotomy) and debridement
• flexor tendon repair
• exposed nerve or tendon
• open wounds not yet ready for flap or graft
• wounds after graft or flap
• crush injuries associated with fractures (open or closed) which do not require stabilization and can therefore accommodate hand motion (for example, an abrasion injury may involve loss of some portion of cortical bone due to friction without losing structural stability sufficient to permit finger motion).
• Fasciectomy
• Tenolysis

Exclusion Criteria

• • Polytrauma outside of the hand

• Malignancy in the wound
• Patient undergoing active chemotherapy
• Hand wound with any untreated infection
• Contaminated wounds not yet debrided
• Insensate hand
• Non-debrided tunneling wounds
• Necrotizing soft-tissue infections
• Osteomyelitis
• Fractures requiring stabilization.
• Untreated non-enteric fistulas
• Smoker
• Hemophiliac
• Sepsis
• Active cellulitis in the wound area
• Radiation applied directly to the wound
• Patients with allergies to product components: silicone, silicone adhesives and polyurethane films (direct contact with wounds), acrylic adhesives (direct contact with skin), polyethylene fabrics, and super-absorbent powders (polyacrylates within the dressing).
• Patients chronically treated with any of the following medications:

• Anti-coagulants
• Immunosuppressants
• Corticosteroids
• NSAIDs

• Minimum Eligible Age: 22 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Center for Advancing Translational Sciences (NCATS)

NIH

Sponsor Role: collaborator

University of Washington

OTHER

Sponsor Role: lead

Responsible Party

Christopher Allan

Associate Professor, School of Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Christopher H Allan, MD

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

University of Washington

Seattle, Washington, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Karen Adams

Role: CONTACT

knadams1@uw.edu

206 354 3360

Facility Contacts

Brandon Bowen

Role: primary

coalcat@uw.edu

206-549-1085

Other Identifiers

UL1TR002319

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY00017024

Identifier Type: -

Identifier Source: org_study_id